Hrt Financial LP Tcr2 Therapeutics Inc. Transaction History

Hrt Financial LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$1.0 - $1.62 $1,840 - $2,980	-1,840 Reduced 14.3%	11,024 $16,000
Q4 2022 Feb 10, 2023	BUY	$0.83 - $1.44 $10,677 - $18,524	12,864 New	12,864 $12,000
Q1 2022 May 16, 2022	SELL	$2.4 - $4.71 $391,432 - $768,186	-163,097 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.58 - $8.34 $700,799 - $1.28 Million	153,013 Added 1517.38%	163,097 $760,000
Q3 2021 Nov 15, 2021	SELL	$8.44 - $18.35 $7,731 - $16,808	-916 Reduced 8.33%	10,084 $85,000

Q2 2021 Aug 16, 2021	BUY	$16.41 - $24.71 $180,510 - $271,810	11,000 New	11,000 $180,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.